Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Resident, Medicine, Johns Hopkins University School of Medicine 2004 - 2006
  • Intern, Medicine, Johns Hopkins University School of Medicine 2003 - 2004
  • M.D., University of Pennsylvania, School of Medicine 2003
• 

  Duke Appointment History

  • Assistant Professor of Medicine, Medicine, Pulmonary, Allergy, and Critical Care Medicine, Medicine 2014 - 2019
• Research
• 

  Selected Grants

  • Open-label extension study to evaluate the long-term safety and tolerability of dupilumab in patients with asthma who participated in a previous dupilumab asthma clinical study awarded by Sanofi US 2017 - 2020
  • A randomized, double-blind, placebo-controlled, parallel-group, Proof-of-Concept (PoC) study to assess the efficacy, safety and tolerability of SAR440340, in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) awarded by Sanofi US 2019 - 2020
  • Redifining Therapy in Early COPD (RETHINC) Trial (Industry Sponsored) awarded by Sunovion Pharmaceuticals, Inc 2017 - 2019
  • A randomized, double-blind, chronic dosing placebo-controlled, parallel group, multicenter, Phase III study to evaluate the efficacy and safety of 2 doses of benralizumab (MEDI-563) in patients with moderate to very severe COPD with a history of COPD awarded by AstraZeneca Pharmaceuticals, LP 2016 - 2019
  • D3250C00037 A multicenter, open-label, safety extension study with benralizumab (MEDI-563) for asthmatic adults on inhaled corticosteroid plus long-acting ss2 agonist (MELTEMI) awarded by AstraZeneca AB 2016 - 2019
  • A multicentre, randomized, parallel group, Phase 3 safety extension study to evaluate the safety and tolerability of benralizumab (MEDI-563) in asthmatic adults and adolescents on inhaled corticosteroid plus long-acting ss2 agonist (BORA) awarded by AstraZeneca AB 2015 - 2018
  • SANOFI EFC-13579 (SAR231893) awarded by Sanofi US 2016 - 2018
  • A multi-centre, open label, single arm, 32-week treatment study in subjects with severe eosinophilic asthma not optimally controlled with current omalizumab treatment who are switched from omalizumab to mepolizumab 100 mg subcutaneous-the OSMO study awarded by GlaxoSmithKline 2016 - 2017
  • MEA117106: Mepolizumab v. Placebo as add-on treatment for frequently exacerbating COPD patients awarded by GlaxoSmithKline 2014 - 2017
• 

  External Relationships

  • Horizon CME/Pri-Med
  • Practicing Clinicians Exchange
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • Scialla, Timothy J., and Kerri L. Cavanaugh. “The rare needle in a diagnostic haystack.” Am J Med 118, no. 7 (July 2005): 720–22. https://doi.org/10.1016/j.amjmed.2005.05.014.
       Full Text  Link to Item
    • Xu, Qing, Serge-Emile Simpson, Timothy J. Scialla, Adam Bagg, and Martin Carroll. “Survival of acute myeloid leukemia cells requires PI3 kinase activation.” Blood 102, no. 3 (August 1, 2003): 972–80. https://doi.org/10.1182/blood-2002-11-3429.
       Full Text  Link to Item
    • Scialla, S., R. Cole, T. Scialla, L. Bednarz, and J. Scheerer. “Rehabilitation for elderly patients with cancer asthenia: making a transition to palliative care.” Palliat Med 14, no. 2 (March 2000): 121–27. https://doi.org/10.1191/026921600666299204.
       Full Text  Link to Item

  • Conference Papers

    • Holguin, F., S. Sharma, D. E. Winnica, K. Wasil, V. L. Smith, M. H. Cruse, N. Perez, et al. “L-Citrulline as Add-On Therapy to Increase Exhaled Nitric Oxide and Improve Lung Function and Asthma Control in Obese Asthmatics.” In American Journal of Respiratory and Critical Care Medicine, Vol. 199. AMER THORACIC SOC, 2019.
       Link to Item
    • Scialla, T. J., M. McCormack, P. Breysse, E. Matsui, and G. B. Diette. “Weight, Diet, and Energy Expenditure in Preschool-Age Inner City Children with and without Asthma.” In American Journal of Respiratory and Critical Care Medicine, Vol. 179. AMER THORACIC SOC, 2009.
       Link to Item
• Teaching & Mentoring
• 

  Recent Courses

  • INTERDIS 450C: Capstone 2019
  • MEDICINE 430C: Pulmonary Medicine 2019
  • INTERDIS 450C: Capstone 2018
  • MEDICINE 430C: Pulmonary Medicine 2018

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.